Antitrust Antitrust

Gilead, Teva head for trial in HIV drug pay-for-delay case as settlement talks falter

Gilead and Teva are set to head to trial tomorrow with plaintiffs suing them over allegedly illegal pay-for-delay agreements for HIV drugs after lawyers for the two sides confirmed that settlement talks have not yielded results.
US District Judge Edward Chen, who has previously encouraged the companies to settle, today

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent


Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Mike Swift

Chief Global Digital Risk Correspondent


Mike Swift is an award-winning journalist who has been at the forefront of covering data, privacy and cybersecurity regulatory news for more than a decade. As the Chief Global Digital Risk Correspondent for MLex, in addition to reporting, he coordinates MLex’s worldwide coverage in the practice area. Formerly chief Internet reporter for the San Jose Mercury News and SiliconValley.com, Mike has covered Google, Facebook, Apple, Microsoft, Twitter and other tech companies and has closely tracked technology and regulatory trends in Silicon Valley. He has wide ranging expertise from the business of professional sports to computer-assisted reporting. A former John S. Knight Fellow at Stanford University, he is a graduate of Colby College.

Discover MLex

Stay on top of global regulatory developments

Latest News